Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Company research

BIO-PATH HOLDINGS, INC.

CIK 1133818Updated Oct 6, 2026

Name history
BIO-PATH HOLDINGS INC · through Apr 5, 2024OGDEN GOLF CO CORP · through Feb 19, 2008

BPTH price & chart

Provider market data

Loading TradingView…

OTC:BPTH on TradingView ↗

TradingView · Data may be delayed

About the company

We are a clinical and preclinical stage oncology and obesity-focused RNAi nanoparticle drug development company utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. Our drug delivery and antisense technology, called DNAbilize®, is a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body’s enzymes when circulating in vivo, incorporated inside of a lipid bilayer having neutral charge. We believe this combination allows for high efficiency loading of antisense DNA into non-toxic, cell-membrane-like structures for delivery of the antisense drug substance into cells. In vivo, the DNAbilize® delivered antisense drug substances are systemically distributed throughout the body to allow for reduction or elimination of target proteins in blood diseases and solid tumors. Through testing in numerous animal studies and dosing in clinical trials, our DNAbilize® drug candidates have demonstrated an excellent safety profile. DNAbilize® is a registered trademark of the Company.

S-1/A · 2025-02-12 · 0001104659-25-011965

Company description from the cited filing.

In the news

No coverage from other publishers is available.

SEC disclosures

Financials

FY 2024 · USD
Revenue— · FY 2024
Net income-9,894,000USD · FY 2024
Source

10-K · 2025-03-27 · 0001558370-25-003837

2024-01-01 to 2024-12-31

Cash— · FY 2024
Operating income-11,992,000USD · FY 2024
Source

10-K · 2025-03-27 · 0001558370-25-003837

2024-01-01 to 2024-12-31

Diluted EPS-4.12USD per share · FY 2024
Source

10-K · 2025-03-27 · 0001558370-25-003837

2024-01-01 to 2024-12-31

Some figures are unavailable for this reporting year.

balance sheet · annual statements
Line itemQ3 2025Q3 2024Q3 2023Q2 2025Q2 2024Q1 2026Q1 2025Q1 2024FY 2024FY 2023FY 2022FY 2021
ASSETS
AssetsUSD690,000
Source

10-Q · 2026-01-13 · 0001663577-26-000009

As of 2025-09-30

2,965,000
Source

10-Q · 2024-11-14 · 0001558370-24-015717

As of 2024-09-30

5,021,000
Source

10-Q · 2023-11-14 · 0001558370-23-019024

As of 2023-09-30

746,000
Source

10-Q · 2025-08-14 · 0001558370-25-011591

As of 2025-06-30

5,118,000
Source

10-Q · 2024-08-14 · 0001558370-24-012259

As of 2024-06-30

677,000
Source

10-Q · 2026-05-20 · 0001663577-26-000156

As of 2026-03-31

2,195,000
Source

10-Q · 2025-05-15 · 0001558370-25-007887

As of 2025-03-31

1,768,000
Source

10-Q · 2024-05-14 · 0001558370-24-008135

As of 2024-03-31

3,883,000
Source

10-K · 2025-03-27 · 0001558370-25-003837

As of 2024-12-31

3,220,000
Source

10-K · 2024-03-07 · 0001558370-24-002730

As of 2023-12-31

15,971,000
Source

10-K · 2023-03-30 · 0001558370-23-005081

As of 2022-12-31

26,568,000
Source

10-K · 2022-03-10 · 0001558370-22-003298

As of 2021-12-31

Property, Plant and Equipment, NetUSD—42,000
Source

10-Q · 2024-11-14 · 0001558370-24-015717

As of 2024-09-30

92,000
Source

10-Q · 2023-11-14 · 0001558370-23-019024

As of 2023-09-30

9,000
Source

10-Q · 2025-08-14 · 0001558370-25-011591

As of 2025-06-30

48,000
Source

10-Q · 2024-08-14 · 0001558370-24-012259

As of 2024-06-30

—21,000
Source

10-Q · 2025-05-15 · 0001558370-25-007887

As of 2025-03-31

54,000
Source

10-Q · 2024-05-14 · 0001558370-24-008135

As of 2024-03-31

23,000
Source

10-K · 2025-03-27 · 0001558370-25-003837

As of 2024-12-31

76,000
Source

10-K · 2024-03-07 · 0001558370-24-002730

As of 2023-12-31

158,000
Source

10-K · 2023-03-30 · 0001558370-23-005081

As of 2022-12-31

225,000
Source

10-K · 2022-03-10 · 0001558370-22-003298

As of 2021-12-31

Current assets:
Assets, CurrentUSD663,000
Source

10-Q · 2026-01-13 · 0001663577-26-000009

As of 2025-09-30

2,899,000
Source

10-Q · 2024-11-14 · 0001558370-24-015717

As of 2024-09-30

4,802,000
Source

10-Q · 2023-11-14 · 0001558370-23-019024

As of 2023-09-30

680,000
Source

10-Q · 2025-08-14 · 0001558370-25-011591

As of 2025-06-30

5,019,000
Source

10-Q · 2024-08-14 · 0001558370-24-012259

As of 2024-06-30

677,000
Source

10-Q · 2026-05-20 · 0001663577-26-000156

As of 2026-03-31

2,120,000
Source

10-Q · 2025-05-15 · 0001558370-25-007887

As of 2025-03-31

1,637,000
Source

10-Q · 2024-05-14 · 0001558370-24-008135

As of 2024-03-31

3,776,000
Source

10-K · 2025-03-27 · 0001558370-25-003837

As of 2024-12-31

3,042,000
Source

10-K · 2024-03-07 · 0001558370-24-002730

As of 2023-12-31

15,615,000
Source

10-K · 2023-03-30 · 0001558370-23-005081

As of 2022-12-31

26,140,000
Source

10-K · 2022-03-10 · 0001558370-22-003298

As of 2021-12-31

Operating Lease, Right-of-Use AssetUSD27,000
Source

10-Q · 2026-01-13 · 0001663577-26-000009

As of 2025-09-30

24,000
Source

10-Q · 2024-11-14 · 0001558370-24-015717

As of 2024-09-30

127,000
Source

10-Q · 2023-11-14 · 0001558370-23-019024

As of 2023-09-30

57,000
Source

10-Q · 2025-08-14 · 0001558370-25-011591

As of 2025-06-30

51,000
Source

10-Q · 2024-08-14 · 0001558370-24-012259

As of 2024-06-30

—54,000
Source

10-Q · 2025-05-15 · 0001558370-25-007887

As of 2025-03-31

77,000
Source

10-Q · 2024-05-14 · 0001558370-24-008135

As of 2024-03-31

84,000
Source

10-K · 2025-03-27 · 0001558370-25-003837

As of 2024-12-31

102,000
Source

10-K · 2024-03-07 · 0001558370-24-002730

As of 2023-12-31

198,000
Source

10-K · 2023-03-30 · 0001558370-23-005081

As of 2022-12-31

203,000
Source

10-K · 2022-03-10 · 0001558370-22-003298

As of 2021-12-31

LIABILITIES AND EQUITY
LiabilitiesUSD8,694,000
Source

10-Q · 2026-01-13 · 0001663577-26-000009

As of 2025-09-30

3,677,000
Source

10-Q · 2024-11-14 · 0001558370-24-015717

As of 2024-09-30

2,496,000
Source

10-Q · 2023-11-14 · 0001558370-23-019024

As of 2023-09-30

7,904,000
Source

10-Q · 2025-08-14 · 0001558370-25-011591

As of 2025-06-30

3,827,000
Source

10-Q · 2024-08-14 · 0001558370-24-012259

As of 2024-06-30

9,163,000
Source

10-Q · 2026-05-20 · 0001663577-26-000156

As of 2026-03-31

4,784,000
Source

10-Q · 2025-05-15 · 0001558370-25-007887

As of 2025-03-31

4,393,000
Source

10-Q · 2024-05-14 · 0001558370-24-008135

As of 2024-03-31

3,729,000
Source

10-K · 2025-03-27 · 0001558370-25-003837

As of 2024-12-31

2,779,000
Source

10-K · 2024-03-07 · 0001558370-24-002730

As of 2023-12-31

1,797,000
Source

10-K · 2023-03-30 · 0001558370-23-005081

As of 2022-12-31

1,111,000
Source

10-K · 2022-03-10 · 0001558370-22-003298

As of 2021-12-31

Stockholders’ equity:
Common Stock, Value, IssuedUSD9,000
Source

10-Q · 2026-01-13 · 0001663577-26-000009

As of 2025-09-30

4,000
Source

10-Q · 2024-11-14 · 0001558370-24-015717

As of 2024-09-30

11,000
Source

10-Q · 2023-11-14 · 0001558370-23-019024

As of 2023-09-30

8,000
Source

10-Q · 2025-08-14 · 0001558370-25-011591

As of 2025-06-30

2,000
Source

10-Q · 2024-08-14 · 0001558370-24-012259

As of 2024-06-30

10,000
Source

10-Q · 2026-05-20 · 0001663577-26-000156

As of 2026-03-31

8,000
Source

10-Q · 2025-05-15 · 0001558370-25-007887

As of 2025-03-31

1,000
Source

10-Q · 2024-05-14 · 0001558370-24-008135

As of 2024-03-31

6,000
Source

10-K · 2025-03-27 · 0001558370-25-003837

As of 2024-12-31

1,000
Source

10-K · 2024-03-07 · 0001558370-24-002730

As of 2023-12-31

8,000
Source

10-K · 2023-03-30 · 0001558370-23-005081

As of 2022-12-31

7,000
Source

10-K · 2022-03-10 · 0001558370-22-003298

As of 2021-12-31

Additional Paid in CapitalUSD117,912,000
Source

10-Q · 2026-01-13 · 0001663577-26-000009

As of 2025-09-30

114,032,000
Source

10-Q · 2024-11-14 · 0001558370-24-015717

As of 2024-09-30

106,749,000
Source

10-Q · 2023-11-14 · 0001558370-23-019024

As of 2023-09-30

117,784,000
Source

10-Q · 2025-08-14 · 0001558370-25-011591

As of 2025-06-30

113,922,000
Source

10-Q · 2024-08-14 · 0001558370-24-012259

As of 2024-06-30

117,948,000
Source

10-Q · 2026-05-20 · 0001663577-26-000156

As of 2026-03-31

117,756,000
Source

10-Q · 2025-05-15 · 0001558370-25-007887

As of 2025-03-31

108,138,000
Source

10-Q · 2024-05-14 · 0001558370-24-008135

As of 2024-03-31

117,649,000
Source

10-K · 2025-03-27 · 0001558370-25-003837

As of 2024-12-31

108,047,000
Source

10-K · 2024-03-07 · 0001558370-24-002730

As of 2023-12-31

105,695,000
Source

10-K · 2023-03-30 · 0001558370-23-005081

As of 2022-12-31

103,111,000
Source

10-K · 2022-03-10 · 0001558370-22-003298

As of 2021-12-31

Retained Earnings (Accumulated Deficit)USD-125,926,000
Source

10-Q · 2026-01-13 · 0001663577-26-000009

As of 2025-09-30

-114,748,000
Source

10-Q · 2024-11-14 · 0001558370-24-015717

As of 2024-09-30

-104,235,000
Source

10-Q · 2023-11-14 · 0001558370-23-019024

As of 2023-09-30

-124,950,000
Source

10-Q · 2025-08-14 · 0001558370-25-011591

As of 2025-06-30

-112,633,000
Source

10-Q · 2024-08-14 · 0001558370-24-012259

As of 2024-06-30

-126,445,000
Source

10-Q · 2026-05-20 · 0001663577-26-000156

As of 2026-03-31

-120,353,000
Source

10-Q · 2025-05-15 · 0001558370-25-007887

As of 2025-03-31

-110,764,000
Source

10-Q · 2024-05-14 · 0001558370-24-008135

As of 2024-03-31

-117,501,000
Source

10-K · 2025-03-27 · 0001558370-25-003837

As of 2024-12-31

-107,607,000
Source

10-K · 2024-03-07 · 0001558370-24-002730

As of 2023-12-31

-91,529,000
Source

10-K · 2023-03-30 · 0001558370-23-005081

As of 2022-12-31

-77,661,000
Source

10-K · 2022-03-10 · 0001558370-22-003298

As of 2021-12-31

Stockholders' Equity Attributable to ParentUSD-8,004,000
Source

10-Q · 2026-01-13 · 0001663577-26-000009

As of 2025-09-30

-712,000
Source

10-Q · 2026-01-13 · 0001663577-26-000009

As of 2024-09-30

2,525,000
Source

10-Q · 2023-11-14 · 0001558370-23-019024

As of 2023-09-30

-7,158,000
Source

10-Q · 2025-08-14 · 0001558370-25-011591

As of 2025-06-30

1,291,000
Source

10-Q · 2024-08-14 · 0001558370-24-012259

As of 2024-06-30

-8,486,000
Source

10-Q · 2026-05-20 · 0001663577-26-000156

As of 2026-03-31

-2,589,000
Source

10-Q · 2026-05-20 · 0001663577-26-000156

As of 2025-03-31

-2,625,000
Source

10-Q · 2024-05-14 · 0001558370-24-008135

As of 2024-03-31

154,000
Source

10-K · 2025-03-27 · 0001558370-25-003837

As of 2024-12-31

441,000
Source

10-K · 2024-03-07 · 0001558370-24-002730

As of 2023-12-31

14,174,000
Source

10-K · 2023-03-30 · 0001558370-23-005081

As of 2022-12-31

25,457,000
Source

10-K · 2022-03-10 · 0001558370-22-003298

As of 2021-12-31

Liabilities and EquityUSD690,000
Source

10-Q · 2026-01-13 · 0001663577-26-000009

As of 2025-09-30

2,965,000
Source

10-Q · 2024-11-14 · 0001558370-24-015717

As of 2024-09-30

5,021,000
Source

10-Q · 2023-11-14 · 0001558370-23-019024

As of 2023-09-30

746,000
Source

10-Q · 2025-08-14 · 0001558370-25-011591

As of 2025-06-30

5,118,000
Source

10-Q · 2024-08-14 · 0001558370-24-012259

As of 2024-06-30

677,000
Source

10-Q · 2026-05-20 · 0001663577-26-000156

As of 2026-03-31

2,195,000
Source

10-Q · 2025-05-15 · 0001558370-25-007887

As of 2025-03-31

1,768,000
Source

10-Q · 2024-05-14 · 0001558370-24-008135

As of 2024-03-31

3,883,000
Source

10-K · 2025-03-27 · 0001558370-25-003837

As of 2024-12-31

3,220,000
Source

10-K · 2024-03-07 · 0001558370-24-002730

As of 2023-12-31

15,971,000
Source

10-K · 2023-03-30 · 0001558370-23-005081

As of 2022-12-31

26,568,000
Source

10-K · 2022-03-10 · 0001558370-22-003298

As of 2021-12-31

Current liabilities:
Liabilities, CurrentUSD8,683,000
Source

10-Q · 2026-01-13 · 0001663577-26-000009

As of 2025-09-30

3,375,000
Source

10-Q · 2024-11-14 · 0001558370-24-015717

As of 2024-09-30

1,357,000
Source

10-Q · 2023-11-14 · 0001558370-23-019024

As of 2023-09-30

7,864,000
Source

10-Q · 2025-08-14 · 0001558370-25-011591

As of 2025-06-30

3,010,000
Source

10-Q · 2024-08-14 · 0001558370-24-012259

As of 2024-06-30

9,151,000
Source

10-Q · 2026-05-20 · 0001663577-26-000156

As of 2026-03-31

4,744,000
Source

10-Q · 2025-05-15 · 0001558370-25-007887

As of 2025-03-31

3,812,000
Source

10-Q · 2024-05-14 · 0001558370-24-008135

As of 2024-03-31

3,295,000
Source

10-K · 2025-03-27 · 0001558370-25-003837

As of 2024-12-31

1,906,000
Source

10-K · 2024-03-07 · 0001558370-24-002730

As of 2023-12-31

1,684,000
Source

10-K · 2023-03-30 · 0001558370-23-005081

As of 2022-12-31

958,000
Source

10-K · 2022-03-10 · 0001558370-22-003298

As of 2021-12-31

Operating Lease, Liability, CurrentUSD27,000
Source

10-Q · 2026-01-13 · 0001663577-26-000009

As of 2025-09-30

26,000
Source

10-Q · 2024-11-14 · 0001558370-24-015717

As of 2024-09-30

116,000
Source

10-Q · 2023-11-14 · 0001558370-23-019024

As of 2023-09-30

57,000
Source

10-Q · 2025-08-14 · 0001558370-25-011591

As of 2025-06-30

55,000
Source

10-Q · 2024-08-14 · 0001558370-24-012259

As of 2024-06-30

—54,000
Source

10-Q · 2025-05-15 · 0001558370-25-007887

As of 2025-03-31

82,000
Source

10-Q · 2024-05-14 · 0001558370-24-008135

As of 2024-03-31

83,000
Source

10-K · 2025-03-27 · 0001558370-25-003837

As of 2024-12-31

103,000
Source

10-K · 2024-03-07 · 0001558370-24-002730

As of 2023-12-31

108,000
Source

10-K · 2023-03-30 · 0001558370-23-005081

As of 2022-12-31

82,000
Source

10-K · 2022-03-10 · 0001558370-22-003298

As of 2021-12-31

Accounts Payable, CurrentUSD4,898,000
Source

10-Q · 2026-01-13 · 0001663577-26-000009

As of 2025-09-30

1,036,000
Source

10-Q · 2024-11-14 · 0001558370-24-015717

As of 2024-09-30

277,000
Source

10-Q · 2023-11-14 · 0001558370-23-019024

As of 2023-09-30

3,479,000
Source

10-Q · 2025-08-14 · 0001558370-25-011591

As of 2025-06-30

766,000
Source

10-Q · 2024-08-14 · 0001558370-24-012259

As of 2024-06-30

5,158,000
Source

10-Q · 2026-05-20 · 0001663577-26-000156

As of 2026-03-31

2,438,000
Source

10-Q · 2025-05-15 · 0001558370-25-007887

As of 2025-03-31

1,746,000
Source

10-Q · 2024-05-14 · 0001558370-24-008135

As of 2024-03-31

1,274,000
Source

10-K · 2025-03-27 · 0001558370-25-003837

As of 2024-12-31

457,000
Source

10-K · 2024-03-07 · 0001558370-24-002730

As of 2023-12-31

667,000
Source

10-K · 2023-03-30 · 0001558370-23-005081

As of 2022-12-31

106,000
Source

10-K · 2022-03-10 · 0001558370-22-003298

As of 2021-12-31

Operating Lease, Liability, NoncurrentUSD——25,000
Source

10-Q · 2023-11-14 · 0001558370-23-019024

As of 2023-09-30

————3,000
Source

10-Q · 2024-05-14 · 0001558370-24-008135

As of 2024-03-31

—10,000
Source

10-K · 2024-03-07 · 0001558370-24-002730

As of 2023-12-31

113,000
Source

10-K · 2023-03-30 · 0001558370-23-005081

As of 2022-12-31

153,000
Source

10-K · 2022-03-10 · 0001558370-22-003298

As of 2021-12-31

Additional Financial Items
Accrued Liabilities, CurrentUSD2,963,000
Source

10-Q · 2026-01-13 · 0001663577-26-000009

As of 2025-09-30

2,313,000
Source

10-Q · 2024-11-14 · 0001558370-24-015717

As of 2024-09-30

964,000
Source

10-Q · 2023-11-14 · 0001558370-23-019024

As of 2023-09-30

3,906,000
Source

10-Q · 2025-08-14 · 0001558370-25-011591

As of 2025-06-30

2,189,000
Source

10-Q · 2024-08-14 · 0001558370-24-012259

As of 2024-06-30

3,020,000
Source

10-Q · 2026-05-20 · 0001663577-26-000156

As of 2026-03-31

1,991,000
Source

10-Q · 2025-05-15 · 0001558370-25-007887

As of 2025-03-31

1,984,000
Source

10-Q · 2024-05-14 · 0001558370-24-008135

As of 2024-03-31

1,938,000
Source

10-K · 2025-03-27 · 0001558370-25-003837

As of 2024-12-31

1,346,000
Source

10-K · 2024-03-07 · 0001558370-24-002730

As of 2023-12-31

909,000
Source

10-K · 2023-03-30 · 0001558370-23-005081

As of 2022-12-31

770,000
Source

10-K · 2022-03-10 · 0001558370-22-003298

As of 2021-12-31

Cash and Cash Equivalents, at Carrying Value—
Source

10-Q · 2026-01-13 · 0001663577-26-000009

As of 2025-09-30

———————————
Preferred Stock, Value, Issued——
Source

10-Q · 2024-11-14 · 0001558370-24-015717

As of 2024-09-30

——
Source

10-Q · 2025-08-14 · 0001558370-25-011591

As of 2025-06-30

——
Source

10-Q · 2026-05-20 · 0001663577-26-000156

As of 2026-03-31

—
Source

10-Q · 2025-05-15 · 0001558370-25-007887

As of 2025-03-31

—————

Lines labelled “Derived” are calculated from reported figures.

cash flow · annual statements
Line itemQ4 2024Q3 2025Q3 2024Q2 2025Q2 2024Q1 2026Q1 2025Q1 2024FY 2024FY 2023FY 2022FY 2021
Cash flows from operating activities:
Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD——————-2,852,000
Source

10-Q · 2025-05-15 · 0001558370-25-007887

2025-01-01 to 2025-03-31

-3,157,000
Source

10-Q · 2025-05-15 · 0001558370-25-007887

2024-01-01 to 2024-03-31

-9,894,000
Source

10-K · 2025-03-27 · 0001558370-25-003837

2024-01-01 to 2024-12-31

-16,078,000
Source

10-K · 2024-03-07 · 0001558370-24-002730

2023-01-01 to 2023-12-31

——
Adjustments to reconcile net income to net cash provided by operating activities:
Share-based Payment Arrangement, Noncash ExpenseUSD—————5,000
Source

10-Q · 2026-05-20 · 0001663577-26-000156

2026-01-01 to 2026-03-31

108,000
Source

10-Q · 2026-05-20 · 0001663577-26-000156

2025-01-01 to 2025-03-31

170,000
Source

10-Q · 2025-05-15 · 0001558370-25-007887

2024-01-01 to 2024-03-31

566,000
Source

10-K · 2025-03-27 · 0001558370-25-003837

2024-01-01 to 2024-12-31

734,000
Source

10-K · 2024-03-07 · 0001558370-24-002730

2023-01-01 to 2023-12-31

851,000
Source

10-K · 2023-03-30 · 0001558370-23-005081

2022-01-01 to 2022-12-31

821,000
Source

10-K · 2022-03-10 · 0001558370-22-003298

2021-01-01 to 2021-12-31

Net Cash Provided by (Used in) Operating ActivitiesUSD—————-38,000
Source

10-Q · 2026-05-20 · 0001663577-26-000156

2026-01-01 to 2026-03-31

-1,313,000
Source

10-Q · 2026-05-20 · 0001663577-26-000156

2025-01-01 to 2025-03-31

-1,038,000
Source

10-Q · 2025-05-15 · 0001558370-25-007887

2024-01-01 to 2024-03-31

-10,575,000
Source

10-K · 2025-03-27 · 0001558370-25-003837

2024-01-01 to 2024-12-31

-11,535,000
Source

10-K · 2024-03-07 · 0001558370-24-002730

2023-01-01 to 2023-12-31

-15,103,000
Source

10-K · 2023-03-30 · 0001558370-23-005081

2022-01-01 to 2022-12-31

-9,917,000
Source

10-K · 2022-03-10 · 0001558370-22-003298

2021-01-01 to 2021-12-31

Cash flows from investing activities:
Net Cash Provided by (Used in) Investing ActivitiesUSD——————————-21,000
Source

10-K · 2023-03-30 · 0001558370-23-005081

2022-01-01 to 2022-12-31

-70,000
Source

10-K · 2022-03-10 · 0001558370-22-003298

2021-01-01 to 2021-12-31

Payments to Acquire Property, Plant, and EquipmentUSD——————————21,000
Source

10-K · 2023-03-30 · 0001558370-23-005081

2022-01-01 to 2022-12-31

70,000
Source

10-K · 2022-03-10 · 0001558370-22-003298

2021-01-01 to 2021-12-31

Cash flows from financing activities:
Net Cash Provided by (Used in) Financing ActivitiesUSD—————50,000
Source

10-Q · 2026-05-20 · 0001663577-26-000156

2026-01-01 to 2026-03-31

262,000
Source

10-Q · 2026-05-20 · 0001663577-26-000156

2025-01-01 to 2025-03-31

174,000
Source

10-Q · 2025-05-15 · 0001558370-25-007887

2024-01-01 to 2024-03-31

10,696,000
Source

10-K · 2025-03-27 · 0001558370-25-003837

2024-01-01 to 2024-12-31

2,203,000
Source

10-K · 2024-03-07 · 0001558370-24-002730

2023-01-01 to 2023-12-31

1,734,000
Source

10-K · 2023-03-30 · 0001558370-23-005081

2022-01-01 to 2022-12-31

20,006,000
Source

10-K · 2022-03-10 · 0001558370-22-003298

2021-01-01 to 2021-12-31

Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD—————12,000
Source

10-Q · 2026-05-20 · 0001663577-26-000156

2026-01-01 to 2026-03-31

-1,051,000
Source

10-Q · 2026-05-20 · 0001663577-26-000156

2025-01-01 to 2025-03-31

-864,000
Source

10-Q · 2025-05-15 · 0001558370-25-007887

2024-01-01 to 2024-03-31

121,000
Source

10-K · 2025-03-27 · 0001558370-25-003837

2024-01-01 to 2024-12-31

-9,332,000
Source

10-K · 2024-03-07 · 0001558370-24-002730

2023-01-01 to 2023-12-31

-13,390,000
Source

10-K · 2023-03-30 · 0001558370-23-005081

2022-01-01 to 2022-12-31

10,019,000
Source

10-K · 2022-03-10 · 0001558370-22-003298

2021-01-01 to 2021-12-31

Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD——562,000
Source

10-Q · 2026-01-13 · 0001663577-26-000009

As of 2024-09-30

0
Source

10-Q · 2025-08-14 · 0001558370-25-011591

As of 2025-06-30

4,006,000
Source

10-Q · 2025-08-14 · 0001558370-25-011591

As of 2024-06-30

12,000
Source

10-Q · 2026-05-20 · 0001663577-26-000156

As of 2026-03-31

122,000
Source

10-Q · 2026-05-20 · 0001663577-26-000156

As of 2025-03-31

188,000
Source

10-Q · 2025-05-15 · 0001558370-25-007887

As of 2024-03-31

1,173,000
Source

10-K · 2025-03-27 · 0001558370-25-003837

As of 2024-12-31

1,052,000
Source

10-K · 2024-03-07 · 0001558370-24-002730

As of 2023-12-31

10,384,000
Source

10-K · 2023-03-30 · 0001558370-23-005081

As of 2022-12-31

23,774,000
Source

10-K · 2022-03-10 · 0001558370-22-003298

As of 2021-12-31

Additional Financial Items
Share-based Payment Arrangement, ExpenseUSD—27,000
Source

10-Q · 2026-01-13 · 0001663577-26-000009

2025-07-01 to 2025-09-30

100,000
Source

10-Q · 2026-01-13 · 0001663577-26-000009

2024-07-01 to 2024-09-30

—————600,000
Source

10-K · 2025-03-27 · 0001558370-25-003837

2024-01-01 to 2024-12-31

700,000
Source

10-K · 2024-03-07 · 0001558370-24-002730

2023-01-01 to 2023-12-31

900,000
Source

10-K · 2023-03-30 · 0001558370-23-005081

2022-01-01 to 2022-12-31

800,000
Source

10-K · 2022-03-10 · 0001558370-22-003298

2021-01-01 to 2021-12-31

DepreciationUSD——————2,000
Source

10-Q · 2026-05-20 · 0001663577-26-000156

2025-01-01 to 2025-03-31

22,000
Source

10-Q · 2025-05-15 · 0001558370-25-007887

2024-01-01 to 2024-03-31

53,000
Source

10-K · 2025-03-27 · 0001558370-25-003837

2024-01-01 to 2024-12-31

82,000
Source

10-K · 2024-03-07 · 0001558370-24-002730

2023-01-01 to 2023-12-31

88,000
Source

10-K · 2023-03-30 · 0001558370-23-005081

2022-01-01 to 2022-12-31

76,000
Source

10-K · 2022-03-10 · 0001558370-22-003298

2021-01-01 to 2021-12-31

General and Administrative ExpenseUSD—213,000
Source

10-Q · 2026-01-13 · 0001663577-26-000009

2025-07-01 to 2025-09-30

1,317,000
Source

10-Q · 2026-01-13 · 0001663577-26-000009

2024-07-01 to 2024-09-30

514,000
Source

10-Q · 2025-08-14 · 0001558370-25-011591

2025-04-01 to 2025-06-30

1,165,000
Source

10-Q · 2025-08-14 · 0001558370-25-011591

2024-04-01 to 2024-06-30

259,000
Source

10-Q · 2026-05-20 · 0001663577-26-000156

2026-01-01 to 2026-03-31

1,264,000
Source

10-Q · 2026-05-20 · 0001663577-26-000156

2025-01-01 to 2025-03-31

1,407,000
Source

10-Q · 2025-05-15 · 0001558370-25-007887

2024-01-01 to 2024-03-31

4,697,000
Source

10-K · 2025-03-27 · 0001558370-25-003837

2024-01-01 to 2024-12-31

4,235,000
Source

10-K · 2024-03-07 · 0001558370-24-002730

2023-01-01 to 2023-12-31

4,736,000
Source

10-K · 2023-03-30 · 0001558370-23-005081

2022-01-01 to 2022-12-31

4,533,000
Source

10-K · 2022-03-10 · 0001558370-22-003298

2021-01-01 to 2021-12-31

Income Tax Expense (Benefit)USD————————0
Source

10-K · 2025-03-27 · 0001558370-25-003837

2024-01-01 to 2024-12-31

0
Source

10-K · 2024-03-07 · 0001558370-24-002730

2023-01-01 to 2023-12-31

0
Source

10-K · 2023-03-30 · 0001558370-23-005081

2022-01-01 to 2022-12-31

0
Source

10-K · 2022-03-10 · 0001558370-22-003298

2021-01-01 to 2021-12-31

Investment Income, InterestUSD——4,000
Source

10-Q · 2024-11-14 · 0001558370-24-015717

2024-07-01 to 2024-09-30

—6,000
Source

10-Q · 2025-08-14 · 0001558370-25-011591

2024-04-01 to 2024-06-30

———14,000
Source

10-K · 2025-03-27 · 0001558370-25-003837

2024-01-01 to 2024-12-31

36,000
Source

10-K · 2024-03-07 · 0001558370-24-002730

2023-01-01 to 2023-12-31

33,000
Source

10-K · 2023-03-30 · 0001558370-23-005081

2022-01-01 to 2022-12-31

3,000
Source

10-K · 2022-03-10 · 0001558370-22-003298

2021-01-01 to 2021-12-31

Net Income (Loss) Attributable to ParentUSD—-976,000
Source

10-Q · 2026-01-13 · 0001663577-26-000009

2025-07-01 to 2025-09-30

-2,115,000
Source

10-Q · 2026-01-13 · 0001663577-26-000009

2024-07-01 to 2024-09-30

-4,597,000
Source

10-Q · 2025-08-14 · 0001558370-25-011591

2025-04-01 to 2025-06-30

-1,869,000
Source

10-Q · 2025-08-14 · 0001558370-25-011591

2024-04-01 to 2024-06-30

-270,000
Source

10-Q · 2026-05-20 · 0001663577-26-000156

2026-01-01 to 2026-03-31

-2,852,000
Source

10-Q · 2026-05-20 · 0001663577-26-000156

2025-01-01 to 2025-03-31

-3,157,000
Source

10-Q · 2025-05-15 · 0001558370-25-007887

2024-01-01 to 2024-03-31

-9,894,000
Source

10-K · 2025-03-27 · 0001558370-25-003837

2024-01-01 to 2024-12-31

-16,078,000
Source

10-K · 2024-03-07 · 0001558370-24-002730

2023-01-01 to 2023-12-31

-13,868,000
Source

10-K · 2023-03-30 · 0001558370-23-005081

2022-01-01 to 2022-12-31

-10,440,000
Source

10-K · 2022-03-10 · 0001558370-22-003298

2021-01-01 to 2021-12-31

Nonoperating Income (Expense)USD—-488,000
Source

10-Q · 2026-01-13 · 0001663577-26-000009

2025-07-01 to 2025-09-30

519,000
Source

10-Q · 2026-01-13 · 0001663577-26-000009

2024-07-01 to 2024-09-30

-35,000
Source

10-Q · 2025-08-14 · 0001558370-25-011591

2025-04-01 to 2025-06-30

1,169,000
Source

10-Q · 2025-08-14 · 0001558370-25-011591

2024-04-01 to 2024-06-30

27,000
Source

10-Q · 2026-05-20 · 0001663577-26-000156

2026-01-01 to 2026-03-31

389,000
Source

10-Q · 2026-05-20 · 0001663577-26-000156

2025-01-01 to 2025-03-31

538,000
Source

10-Q · 2025-05-15 · 0001558370-25-007887

2024-01-01 to 2024-03-31

2,098,000
Source

10-K · 2025-03-27 · 0001558370-25-003837

2024-01-01 to 2024-12-31

-235,000
Source

10-K · 2024-03-07 · 0001558370-24-002730

2023-01-01 to 2023-12-31

33,000
Source

10-K · 2023-03-30 · 0001558370-23-005081

2022-01-01 to 2022-12-31

3,000
Source

10-K · 2022-03-10 · 0001558370-22-003298

2021-01-01 to 2021-12-31

Operating ExpensesUSD—488,000
Source

10-Q · 2026-01-13 · 0001663577-26-000009

2025-07-01 to 2025-09-30

2,634,000
Source

10-Q · 2026-01-13 · 0001663577-26-000009

2024-07-01 to 2024-09-30

4,562,000
Source

10-Q · 2025-08-14 · 0001558370-25-011591

2025-04-01 to 2025-06-30

3,038,000
Source

10-Q · 2025-08-14 · 0001558370-25-011591

2024-04-01 to 2024-06-30

297,000
Source

10-Q · 2026-05-20 · 0001663577-26-000156

2026-01-01 to 2026-03-31

3,241,000
Source

10-Q · 2026-05-20 · 0001663577-26-000156

2025-01-01 to 2025-03-31

3,695,000
Source

10-Q · 2025-05-15 · 0001558370-25-007887

2024-01-01 to 2024-03-31

11,992,000
Source

10-K · 2025-03-27 · 0001558370-25-003837

2024-01-01 to 2024-12-31

15,843,000
Source

10-K · 2024-03-07 · 0001558370-24-002730

2023-01-01 to 2023-12-31

13,901,000
Source

10-K · 2023-03-30 · 0001558370-23-005081

2022-01-01 to 2022-12-31

10,443,000
Source

10-K · 2022-03-10 · 0001558370-22-003298

2021-01-01 to 2021-12-31

Proceeds from Issuance of Common StockUSD———————174,000
Source

10-Q · 2025-05-15 · 0001558370-25-007887

2024-01-01 to 2024-03-31

10,696,000
Source

10-K · 2025-03-27 · 0001558370-25-003837

2024-01-01 to 2024-12-31

1,677,000
Source

10-K · 2024-03-07 · 0001558370-24-002730

2023-01-01 to 2023-12-31

1,734,000
Source

10-K · 2023-03-30 · 0001558370-23-005081

2022-01-01 to 2022-12-31

15,849,000
Source

10-K · 2022-03-10 · 0001558370-22-003298

2021-01-01 to 2021-12-31

Proceeds from Stock Options ExercisedUSD———————————4,157,000
Source

10-K · 2022-03-10 · 0001558370-22-003298

2021-01-01 to 2021-12-31

Amortization of Deferred Charges——————
Source

10-Q · 2026-05-20 · 0001663577-26-000156

2026-01-01 to 2026-03-31

—
Source

10-Q · 2026-05-20 · 0001663577-26-000156

2025-01-01 to 2025-03-31

—————

Lines labelled “Derived” are calculated from reported figures.

income statement · annual statements
Line itemQ4 2024Q3 2025Q3 2024Q2 2025Q2 2024Q1 2026Q1 2025Q1 2024FY 2024FY 2023FY 2022FY 2021
Operating Income (Loss)USD—-488,000
Source

10-Q · 2026-01-13 · 0001663577-26-000009

2025-07-01 to 2025-09-30

-2,634,000
Source

10-Q · 2026-01-13 · 0001663577-26-000009

2024-07-01 to 2024-09-30

-4,562,000
Source

10-Q · 2025-08-14 · 0001558370-25-011591

2025-04-01 to 2025-06-30

-3,038,000
Source

10-Q · 2025-08-14 · 0001558370-25-011591

2024-04-01 to 2024-06-30

-297,000
Source

10-Q · 2026-05-20 · 0001663577-26-000156

2026-01-01 to 2026-03-31

-3,241,000
Source

10-Q · 2026-05-20 · 0001663577-26-000156

2025-01-01 to 2025-03-31

-3,695,000
Source

10-Q · 2025-05-15 · 0001558370-25-007887

2024-01-01 to 2024-03-31

-11,992,000
Source

10-K · 2025-03-27 · 0001558370-25-003837

2024-01-01 to 2024-12-31

-15,843,000
Source

10-K · 2024-03-07 · 0001558370-24-002730

2023-01-01 to 2023-12-31

-13,901,000
Source

10-K · 2023-03-30 · 0001558370-23-005081

2022-01-01 to 2022-12-31

-10,443,000
Source

10-K · 2022-03-10 · 0001558370-22-003298

2021-01-01 to 2021-12-31

Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD————————-9,894,000
Source

10-K · 2025-03-27 · 0001558370-25-003837

2024-01-01 to 2024-12-31

-16,078,000
Source

10-K · 2024-03-07 · 0001558370-24-002730

2023-01-01 to 2023-12-31

-13,868,000
Source

10-K · 2023-03-30 · 0001558370-23-005081

2022-01-01 to 2022-12-31

-10,440,000
Source

10-K · 2022-03-10 · 0001558370-22-003298

2021-01-01 to 2021-12-31

Income Tax Expense (Benefit)USD————————0
Source

10-K · 2025-03-27 · 0001558370-25-003837

2024-01-01 to 2024-12-31

0
Source

10-K · 2024-03-07 · 0001558370-24-002730

2023-01-01 to 2023-12-31

0
Source

10-K · 2023-03-30 · 0001558370-23-005081

2022-01-01 to 2022-12-31

0
Source

10-K · 2022-03-10 · 0001558370-22-003298

2021-01-01 to 2021-12-31

Net Income (Loss) Attributable to ParentUSD—-976,000
Source

10-Q · 2026-01-13 · 0001663577-26-000009

2025-07-01 to 2025-09-30

-2,115,000
Source

10-Q · 2026-01-13 · 0001663577-26-000009

2024-07-01 to 2024-09-30

-4,597,000
Source

10-Q · 2025-08-14 · 0001558370-25-011591

2025-04-01 to 2025-06-30

-1,869,000
Source

10-Q · 2025-08-14 · 0001558370-25-011591

2024-04-01 to 2024-06-30

-270,000
Source

10-Q · 2026-05-20 · 0001663577-26-000156

2026-01-01 to 2026-03-31

-2,852,000
Source

10-Q · 2026-05-20 · 0001663577-26-000156

2025-01-01 to 2025-03-31

-3,157,000
Source

10-Q · 2025-05-15 · 0001558370-25-007887

2024-01-01 to 2024-03-31

-9,894,000
Source

10-K · 2025-03-27 · 0001558370-25-003837

2024-01-01 to 2024-12-31

-16,078,000
Source

10-K · 2024-03-07 · 0001558370-24-002730

2023-01-01 to 2023-12-31

-13,868,000
Source

10-K · 2023-03-30 · 0001558370-23-005081

2022-01-01 to 2022-12-31

-10,440,000
Source

10-K · 2022-03-10 · 0001558370-22-003298

2021-01-01 to 2021-12-31

Earnings Per Share, BasicUSD per share——-0.7
Source

10-Q · 2024-11-14 · 0001558370-24-015717

2024-07-01 to 2024-09-30

-0.55
Source

10-Q · 2025-08-14 · 0001558370-25-011591

2025-04-01 to 2025-06-30

-1.16
Source

10-Q · 2025-08-14 · 0001558370-25-011591

2024-04-01 to 2024-06-30

—-0.4
Source

10-Q · 2025-05-15 · 0001558370-25-007887

2025-01-01 to 2025-03-31

-4.88
Source

10-Q · 2025-05-15 · 0001558370-25-007887

2024-01-01 to 2024-03-31

-4.12
Source

10-K · 2025-03-27 · 0001558370-25-003837

2024-01-01 to 2024-12-31

-33.63
Source

10-K · 2024-03-07 · 0001558370-24-002730

2023-01-01 to 2023-12-31

-1.91
Source

10-K · 2023-03-30 · 0001558370-23-005081

2022-01-01 to 2022-12-31

-1.55
Source

10-K · 2022-03-10 · 0001558370-22-003298

2021-01-01 to 2021-12-31

Earnings Per Share, DilutedUSD per share—-0.11
Source

10-Q · 2026-01-13 · 0001663577-26-000009

2025-07-01 to 2025-09-30

-0.7
Source

10-Q · 2026-01-13 · 0001663577-26-000009

2024-07-01 to 2024-09-30

-0.55
Source

10-Q · 2025-08-14 · 0001558370-25-011591

2025-04-01 to 2025-06-30

-1.16
Source

10-Q · 2025-08-14 · 0001558370-25-011591

2024-04-01 to 2024-06-30

-0.03
Source

10-Q · 2026-05-20 · 0001663577-26-000156

2026-01-01 to 2026-03-31

-0.4
Source

10-Q · 2026-05-20 · 0001663577-26-000156

2025-01-01 to 2025-03-31

-4.88
Source

10-Q · 2025-05-15 · 0001558370-25-007887

2024-01-01 to 2024-03-31

-4.12
Source

10-K · 2025-03-27 · 0001558370-25-003837

2024-01-01 to 2024-12-31

-33.63
Source

10-K · 2024-03-07 · 0001558370-24-002730

2023-01-01 to 2023-12-31

-1.91
Source

10-K · 2023-03-30 · 0001558370-23-005081

2022-01-01 to 2022-12-31

-1.55
Source

10-K · 2022-03-10 · 0001558370-22-003298

2021-01-01 to 2021-12-31

Weighted Average Number of Shares Outstanding, Basicshares——3,017,000
Source

10-Q · 2024-11-14 · 0001558370-24-015717

2024-07-01 to 2024-09-30

8,308,000
Source

10-Q · 2025-08-14 · 0001558370-25-011591

2025-04-01 to 2025-06-30

1,612,000
Source

10-Q · 2025-08-14 · 0001558370-25-011591

2024-04-01 to 2024-06-30

—7,062,000
Source

10-Q · 2025-05-15 · 0001558370-25-007887

2025-01-01 to 2025-03-31

647,000
Source

10-Q · 2025-05-15 · 0001558370-25-007887

2024-01-01 to 2024-03-31

2,401,000
Source

10-K · 2025-03-27 · 0001558370-25-003837

2024-01-01 to 2024-12-31

478,000
Source

10-K · 2024-03-07 · 0001558370-24-002730

2023-01-01 to 2023-12-31

7,276,000
Source

10-K · 2023-03-30 · 0001558370-23-005081

2022-01-01 to 2022-12-31

6,725,000
Source

10-K · 2022-03-10 · 0001558370-22-003298

2021-01-01 to 2021-12-31

Weighted Average Number of Shares Outstanding, Dilutedshares—8,521,000
Source

10-Q · 2026-01-13 · 0001663577-26-000009

2025-07-01 to 2025-09-30

3,017,000
Source

10-Q · 2026-01-13 · 0001663577-26-000009

2024-07-01 to 2024-09-30

8,308,000
Source

10-Q · 2025-08-14 · 0001558370-25-011591

2025-04-01 to 2025-06-30

1,612,000
Source

10-Q · 2025-08-14 · 0001558370-25-011591

2024-04-01 to 2024-06-30

9,342,000
Source

10-Q · 2026-05-20 · 0001663577-26-000156

2026-01-01 to 2026-03-31

7,062,000
Source

10-Q · 2026-05-20 · 0001663577-26-000156

2025-01-01 to 2025-03-31

647,000
Source

10-Q · 2025-05-15 · 0001558370-25-007887

2024-01-01 to 2024-03-31

2,401,000
Source

10-K · 2025-03-27 · 0001558370-25-003837

2024-01-01 to 2024-12-31

478,000
Source

10-K · 2024-03-07 · 0001558370-24-002730

2023-01-01 to 2023-12-31

7,276,000
Source

10-K · 2023-03-30 · 0001558370-23-005081

2022-01-01 to 2022-12-31

6,725,000
Source

10-K · 2022-03-10 · 0001558370-22-003298

2021-01-01 to 2021-12-31

Additional Financial Items
General and Administrative ExpenseUSD—213,000
Source

10-Q · 2026-01-13 · 0001663577-26-000009

2025-07-01 to 2025-09-30

1,317,000
Source

10-Q · 2026-01-13 · 0001663577-26-000009

2024-07-01 to 2024-09-30

514,000
Source

10-Q · 2025-08-14 · 0001558370-25-011591

2025-04-01 to 2025-06-30

1,165,000
Source

10-Q · 2025-08-14 · 0001558370-25-011591

2024-04-01 to 2024-06-30

259,000
Source

10-Q · 2026-05-20 · 0001663577-26-000156

2026-01-01 to 2026-03-31

1,264,000
Source

10-Q · 2026-05-20 · 0001663577-26-000156

2025-01-01 to 2025-03-31

1,407,000
Source

10-Q · 2025-05-15 · 0001558370-25-007887

2024-01-01 to 2024-03-31

4,697,000
Source

10-K · 2025-03-27 · 0001558370-25-003837

2024-01-01 to 2024-12-31

4,235,000
Source

10-K · 2024-03-07 · 0001558370-24-002730

2023-01-01 to 2023-12-31

4,736,000
Source

10-K · 2023-03-30 · 0001558370-23-005081

2022-01-01 to 2022-12-31

4,533,000
Source

10-K · 2022-03-10 · 0001558370-22-003298

2021-01-01 to 2021-12-31

Investment Income, InterestUSD——4,000
Source

10-Q · 2024-11-14 · 0001558370-24-015717

2024-07-01 to 2024-09-30

—6,000
Source

10-Q · 2025-08-14 · 0001558370-25-011591

2024-04-01 to 2024-06-30

———14,000
Source

10-K · 2025-03-27 · 0001558370-25-003837

2024-01-01 to 2024-12-31

36,000
Source

10-K · 2024-03-07 · 0001558370-24-002730

2023-01-01 to 2023-12-31

33,000
Source

10-K · 2023-03-30 · 0001558370-23-005081

2022-01-01 to 2022-12-31

3,000
Source

10-K · 2022-03-10 · 0001558370-22-003298

2021-01-01 to 2021-12-31

Nonoperating Income (Expense)USD—-488,000
Source

10-Q · 2026-01-13 · 0001663577-26-000009

2025-07-01 to 2025-09-30

519,000
Source

10-Q · 2026-01-13 · 0001663577-26-000009

2024-07-01 to 2024-09-30

-35,000
Source

10-Q · 2025-08-14 · 0001558370-25-011591

2025-04-01 to 2025-06-30

1,169,000
Source

10-Q · 2025-08-14 · 0001558370-25-011591

2024-04-01 to 2024-06-30

27,000
Source

10-Q · 2026-05-20 · 0001663577-26-000156

2026-01-01 to 2026-03-31

389,000
Source

10-Q · 2026-05-20 · 0001663577-26-000156

2025-01-01 to 2025-03-31

538,000
Source

10-Q · 2025-05-15 · 0001558370-25-007887

2024-01-01 to 2024-03-31

2,098,000
Source

10-K · 2025-03-27 · 0001558370-25-003837

2024-01-01 to 2024-12-31

-235,000
Source

10-K · 2024-03-07 · 0001558370-24-002730

2023-01-01 to 2023-12-31

33,000
Source

10-K · 2023-03-30 · 0001558370-23-005081

2022-01-01 to 2022-12-31

3,000
Source

10-K · 2022-03-10 · 0001558370-22-003298

2021-01-01 to 2021-12-31

Operating ExpensesUSD—488,000
Source

10-Q · 2026-01-13 · 0001663577-26-000009

2025-07-01 to 2025-09-30

2,634,000
Source

10-Q · 2026-01-13 · 0001663577-26-000009

2024-07-01 to 2024-09-30

4,562,000
Source

10-Q · 2025-08-14 · 0001558370-25-011591

2025-04-01 to 2025-06-30

3,038,000
Source

10-Q · 2025-08-14 · 0001558370-25-011591

2024-04-01 to 2024-06-30

297,000
Source

10-Q · 2026-05-20 · 0001663577-26-000156

2026-01-01 to 2026-03-31

3,241,000
Source

10-Q · 2026-05-20 · 0001663577-26-000156

2025-01-01 to 2025-03-31

3,695,000
Source

10-Q · 2025-05-15 · 0001558370-25-007887

2024-01-01 to 2024-03-31

11,992,000
Source

10-K · 2025-03-27 · 0001558370-25-003837

2024-01-01 to 2024-12-31

15,843,000
Source

10-K · 2024-03-07 · 0001558370-24-002730

2023-01-01 to 2023-12-31

13,901,000
Source

10-K · 2023-03-30 · 0001558370-23-005081

2022-01-01 to 2022-12-31

10,443,000
Source

10-K · 2022-03-10 · 0001558370-22-003298

2021-01-01 to 2021-12-31

Research and Development ExpenseUSD—275,000
Source

10-Q · 2026-01-13 · 0001663577-26-000009

2025-07-01 to 2025-09-30

1,317,000
Source

10-Q · 2026-01-13 · 0001663577-26-000009

2024-07-01 to 2024-09-30

4,048,000
Source

10-Q · 2025-08-14 · 0001558370-25-011591

2025-04-01 to 2025-06-30

1,873,000
Source

10-Q · 2025-08-14 · 0001558370-25-011591

2024-04-01 to 2024-06-30

38,000
Source

10-Q · 2026-05-20 · 0001663577-26-000156

2026-01-01 to 2026-03-31

1,977,000
Source

10-Q · 2026-05-20 · 0001663577-26-000156

2025-01-01 to 2025-03-31

2,288,000
Source

10-Q · 2025-05-15 · 0001558370-25-007887

2024-01-01 to 2024-03-31

7,295,000
Source

10-K · 2025-03-27 · 0001558370-25-003837

2024-01-01 to 2024-12-31

11,608,000
Source

10-K · 2024-03-07 · 0001558370-24-002730

2023-01-01 to 2023-12-31

9,165,000
Source

10-K · 2023-03-30 · 0001558370-23-005081

2022-01-01 to 2022-12-31

5,910,000
Source

10-K · 2022-03-10 · 0001558370-22-003298

2021-01-01 to 2021-12-31

Interest Expense, Debt————
Source

10-Q · 2025-08-14 · 0001558370-25-011591

2025-04-01 to 2025-06-30

———
Source

10-Q · 2025-05-15 · 0001558370-25-007887

2025-01-01 to 2025-03-31

—————

Lines labelled “Derived” are calculated from reported figures.

Offerings

Registration 333-284363

S-1/A · 2025-02-12 · 0001104659-25-011965

Terms from the governing filing for this registration; not a claim that the offering is open today.

Filing attachments

bpth-20250501xex99d1.htm · 8-K · 2025-05-02

EX-99.1 2 bpth-20250501xex99d1.htm EX-99.1 Exhibit 99.1 Bio-Path Holdings Achieves Third Pre-Clinical Milestone Confirming Potential of BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients Data suggest BP1001-A prevents fatty acid-induced insulin resistance in cells HOUSTON - May 1, 2025 - Bio-Path Holdings, Inc., (OTCQB:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid …

8-K · 2025-05-02 · 0001558370-25-006150

Read attachment ↗
tm2513536d1_ex4-1.htm · 8-K · 2025-04-29

EX-4.1 2 tm2513536d1_ex4-1.htm EXHIBIT 4.1 Exhibit 4.1 THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT …

8-K · 2025-04-29 · 0001104659-25-041256

Read attachment ↗
bpth-20250328xex99d1.htm · 8-K · 2025-03-28

EX-99.1 2 bpth-20250328xex99d1.htm EX-99.1 Exhibit 99.1 Bio-Path Holdings Reports Full Year 2024 Financial Results Reports Continued Progress Across Both Obesity and Oncology Franchises HOUSTON - March 28, 2025 - Bio-Path Holdings, Inc., (OTCQB:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer and obesity drugs, today announced its financial results for the year ended December …

8-K · 2025-03-28 · 0001558370-25-003922

Read attachment ↗
tm2510724d1_ex4-1.htm · 8-K · 2025-03-28

EX-4.1 2 tm2510724d1_ex4-1.htm EXHIBIT 4.1 Exhibit 4.1 THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT …

8-K · 2025-03-28 · 0001104659-25-029376

Read attachment ↗
bpth-20250318xex99d1.htm · 8-K · 2025-03-19

EX-99.1 2 bpth-20250318xex99d1.htm EX-99.1 Exhibit 99.1 Bio-Path Holdings Announces Pre-Clinical Results Signaling Increased Potential for BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients Recent Pre-Clinical Studies Showed BP1001-A Attenuated Fatty Acid-Induced Insulin Resistance and Restored Insulin Sensitivity in Muscle Progenitor and Skeletal Muscle Fiber Cell Models HOUSTON - March 18, 2025 - Bio-Path Holdings, Inc., (OTCQB:BPTH), a biotechnology company leveraging its pr…

8-K · 2025-03-19 · 0001558370-25-003241

Read attachment ↗
tm258626d1_ex4-1.htm · 8-K · 2025-03-07

EX-4.1 2 tm258626d1_ex4-1.htm EXHIBIT 4.1 Exhibit 4.1 THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT O…

8-K · 2025-03-07 · 0001104659-25-021789

Read attachment ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.